- Home
- WLY vs DYN Comparison
WLY vs DYN Comparison
Compare WLY & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- DYN
- Stock Information
- Founded
- WLY 1807
- DYN 1984
- Country
- WLY United States
- DYN United States
- Employees
- WLY N/A
- DYN N/A
- Industry
- WLY Books
- DYN Medicinal Chemicals and Botanical Products
- Sector
- WLY Consumer Discretionary
- DYN Health Care
- Exchange
- WLY Nasdaq
- DYN Nasdaq
- Market Cap
- WLY 2.2B
- DYN 2.6B
- IPO Year
- WLY N/A
- DYN 2020
- Fundamental
- Price
- WLY $39.48
- DYN $14.01
- Analyst Decision
- WLY
- DYN Strong Buy
- Analyst Count
- WLY 0
- DYN 10
- Target Price
- WLY N/A
- DYN $50.78
- AVG Volume (30 Days)
- WLY 330.7K
- DYN 2.2M
- Earning Date
- WLY 03-06-2025
- DYN 03-04-2025
- Dividend Yield
- WLY 3.57%
- DYN N/A
- EPS Growth
- WLY N/A
- DYN N/A
- EPS
- WLY N/A
- DYN N/A
- Revenue
- WLY $1,759,570,000.00
- DYN N/A
- Revenue This Year
- WLY N/A
- DYN N/A
- Revenue Next Year
- WLY $1.13
- DYN N/A
- P/E Ratio
- WLY N/A
- DYN N/A
- Revenue Growth
- WLY N/A
- DYN N/A
- 52 Week Low
- WLY $32.80
- DYN $13.07
- 52 Week High
- WLY $53.96
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- WLY 34.83
- DYN 37.85
- Support Level
- WLY $39.80
- DYN $13.59
- Resistance Level
- WLY $40.61
- DYN $14.50
- Average True Range (ATR)
- WLY 1.00
- DYN 0.98
- MACD
- WLY 0.01
- DYN 0.32
- Stochastic Oscillator
- WLY 5.81
- DYN 22.90
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.